BerGenBio ASA

Four months after the failure of its lung cancer candidate, Norway’s BerGenBio has chosen to merge with compatriot Oncoinvent and enter the radiopharmaceuticals space. The Bergen-headquartered biotech

The European biotech environment seems to be enjoying something of a revival but it has been a chastening week for three of the continent’s cancer-focused companies that have been forced to look at al

It has been shown for the first time that a combination of two different COVID-19 vaccines can produce high immunogenicity in patients, with no unexpected side-effects. On 18 May, Spain’s Carlos III I

Genmab A/S is not going to advance an antibody-drug conjugate, enapotamab vedotin, into late-stage clinical development, citing stringent proof-of-concept criteria, thereby cementing the biotech’s la